Biogen Idec - Neurology

Biogen Idec - Neurology
Share
Biogen Idec uses cutting-edge science to discover, develop, manufacture, and market biological products for the treatment of serious diseases with a focus on neurological disorders.

Biogen Idec - Neurology

 •  September 15, 2016

New Analysis of “No Evidence of Disease Activity” Data From Phase 3 DECIDE Study Affirms Positive Impact of ZINBRYTA Versus Interferon Beta-1a Interim Analysis of EXTEND Study Shows Sustained ZINBRYTA Efficacy for Up to Five Years Corporate, Neurodegenerative diseases Thursday, September 15, 2016 7:30 am EDT CAMBRIDGE, Mass. & NORTH CHICAGO, Ill....

Biogen Idec - Neurology

 •  September 8, 2016

Largest Study on MS Cost of Illness Reveals New Insights from Patients about the Impact of MS Comparative Effectiveness Studies Reinforce Clinical Data Supporting the Strong, Sustained Efficacy of TECFIDERA ® New ZINBRYTA™ NEDA Analysis Reinforces Efficacy vs. Interferon Beta-1a Corporate, Neurodegenerative diseases Thursday, September 8, 2016...

Biogen Idec - Neurology

 •  August 9, 2016

Bioverativ Will Focus on Accelerating Innovation for People Living with Hemophilia and Other Blood Disorders Initial Form 10 Filing Expected Later This Week On Track for Separation into Two Publicly Traded Companies in Early 2017 Corporate, Hemophilia Spin-off Tuesday, August 9, 2016 9:00 am EDT CAMBRIDGE, Mass. EmailPDFPrintRSS...

Biogen Idec - Neurology

 •  July 18, 2016

Longitudinal Joint Health Data from Patients in the A-LONG, ASPIRE, B-LONG and B-YOND Trials to be Presented Corporate, Rare and Genetic diseases Monday, July 18, 2016 7:30 am EDT CAMBRIDGE, Mass. & STOCKHOLM EmailPDFPrintRSS NASDAQ:BIIBUS09062X1037 STO:SOBI "The breadth of research, for both marketed products and preclinical programs being...

Biogen Idec - Neurology

 •  July 5, 2016

ZINBRYTA Significantly Reduced Multiple Measures of Disease Activity in Patients with Relapsing Forms of MS - - Targeted Mechanism of Action of ZINBRYTA Did Not Cause Broad, Prolonged Depletion of Studied Immune Cell Types -
The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult...

Biogen Idec - Neurology

 •  June 21, 2016

McKenzie to lead technical development and global manufacturing supply for clinical and commercial portfolio
"Our team will continue to build on a very successful track record of safety, quality and reliability to advance our diverse portfolio in biologics, oligonucleotides, gene therapy and small molecules."
Biogen (NASDAQ: BIIB) announced today...

Biogen Idec - Neurology

 •  June 9, 2016

Data confirm safety and efficacy of switching from Enbrel ® and Remicade ® to BENEPALI ® and FLIXABI ® respectively
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI® (etanercept) and FLIXABI® (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB),...

Biogen Idec - Neurology

 •  June 7, 2016

-- Biogen Continues to Analyze Data to Inform Next Step in Clinical Development Program --
Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing...

Biogen Idec - Neurology

 •  May 30, 2016

Biogen to manufacture and commercialize FLIXABI, the company’s second anti-TNF biosimilar therapy in the EU
"We are delighted to be the first company to bring two anti-TNF biosimilars to patients and physicians across Europe."
ZUG, Switzerland--(BUSINESS WIRE)--The European Commission (EC) today granted marketing authorization in the European Union...

Biogen Idec - Neurology

 •  May 27, 2016

Approval Supported by Largest and Longest Head-to-Head Phase 3 Study Conducted in Multiple Sclerosis (MS) ZINBRYTA Significantly Reduced Multiple Measures of Disease Activity in Patients with Relapsing MS Approval Supported by Largest and Longest Head-to-Head Phase 3 Study Conducted in Multiple Sclerosis (MS) ZINBRYTA Significantly Reduced Multiple Measures of Disease Activity in Patients with Relapsing MS
The U.S. Food and Drug Administration (FDA) approved ZINBRYTATM (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for...